ICU Medical (ICUI) Expected to Release Earnings on Thursday

Posted by on Aug 4th, 2026

ICU Medical (NASDAQ:ICUI – Get Free Report) is anticipated to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of $1.91 per share and revenue of $533.3850 million for the quarter. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Individuals can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

ICU Medical (NASDAQ:ICUI – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, topping analysts’ consensus estimates of $1.78 by $0.19. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The company had revenue of $525.77 million during the quarter, compared to the consensus estimate of $520.65 million. During the same quarter last year, the company earned $1.72 EPS. The company’s quarterly revenue was down 12.3% on a year-over-year basis. On average, analysts expect ICU Medical to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $172.34 on Tuesday. The firm has a market capitalization of $4.31 billion, a PE ratio of 93.15, a PEG ratio of 2.35 and a beta of 0.76. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60. ICU Medical has a 1-year low of $107.00 and a 1-year high of $176.27. The business’s 50 day moving average is $148.81 and its 200-day moving average is $140.40.

Insiders Place Their Bets

In other news, VP Virginia Ruth Sanzone sold 2,447 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the sale, the vice president owned 19,460 shares in the company, valued at approximately $2,414,596.80. The trade was a 11.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the sale, the director directly owned 7,960 shares in the company, valued at approximately $978,363.60. The trade was a 23.34% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.10% of the stock is currently owned by company insiders.

Institutional Trading of ICU Medical

Several large investors have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC boosted its holdings in shares of ICU Medical by 11.6% in the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after acquiring an additional 101 shares in the last quarter. Headlands Technologies LLC acquired a new stake in ICU Medical during the 2nd quarter valued at $177,000. O Shaughnessy Asset Management LLC bought a new position in ICU Medical in the 4th quarter valued at $203,000. Panagora Asset Management Inc. acquired a new position in ICU Medical in the fourth quarter worth $205,000. Finally, Janney Montgomery Scott LLC bought a new stake in shares of ICU Medical during the fourth quarter worth $216,000. 96.10% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ICUI shares. Piper Sandler decreased their price target on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. BTIG Research began coverage on shares of ICU Medical in a research note on Monday, June 15th. They issued a “buy” rating and a $170.00 price objective for the company. Weiss Ratings raised shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Needham & Company LLC upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research report on Wednesday, May 27th. Finally, Sanford C. Bernstein cut shares of ICU Medical to a “market perform” rating in a research note on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $172.00.

Get Our Latest Research Report on ICUI

ICU Medical Company Profile

(Get Free Report)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

Featured Stories

Earnings History for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.